In fact, also in this new cohort of progressive MS patients, we could find eLFs—defining them by the combined presence of CD3+ T cells, CD20+ B cells, Ki67+ proliferating, CD35+ or CD21+ (FDCs)? This evidence concerns the gene CR1 and myeloid sarcoma.